Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) EBIT (2020 - 2025)

GeneDx Holdings (WGS) has disclosed EBIT for 6 consecutive years, with -$14.2 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT fell 261.65% to -$14.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$13.1 million, a 43.67% increase, with the full-year FY2025 number at -$13.1 million, up 43.67% from a year prior.
  • EBIT was -$14.2 million for Q4 2025 at GeneDx Holdings, down from -$3.3 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $9.0 million in Q2 2025 to a low of -$324.9 million in Q4 2022.
  • A 5-year average of -$66.5 million and a median of -$44.2 million in 2021 define the central range for EBIT.
  • Biggest YoY gain for EBIT was 184.7% in 2025; the steepest drop was 261.65% in 2025.
  • GeneDx Holdings' EBIT stood at -$115.8 million in 2021, then crashed by 180.6% to -$324.9 million in 2022, then skyrocketed by 92.11% to -$25.6 million in 2023, then surged by 134.34% to $8.8 million in 2024, then tumbled by 261.65% to -$14.2 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's EBIT are -$14.2 million (Q4 2025), -$3.3 million (Q3 2025), and $9.0 million (Q2 2025).